171 Quantifying skeletal burden in fibrous dysplasia using Sodium Fluoride PET/CT References 1. Javaid MK, Boyce A, Appelman-Dijkstra N, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/ MAS international consortium. Orphanet J Rare Dis. 2019;14:139. doi:10.1186/s13023-0191102-9. 2. Collins MT, Kushner H, Reynolds JC, et al. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res. 2005;20:219-26. doi:10.1359/jbmr.041111. 3. Chapurlat RD, Gensburger D, Jimenez-Andrade JM, et al. Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. Orphanet J Rare Dis. 2012;7 Suppl 1:S3. doi:10.1186/1750-1172-7-s1-s3. 4. Collins MT, Riminucci M, Bianco P. Fibrous Dysplasia. In: Rosen C, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 8th ed: John Wiley & Sons, Inc.; 2013. p. 786-93. 5. Majoor BC, Appelman-Dijkstra NM, Fiocco M, et al. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. J Bone Miner Res. 2017;32:264-76. doi:10.1002/ jbmr.2999. 6. Rohren EM, Etchebehere EC, Araujo JC, et al . Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med. 2015;56:1507-12. doi:10.2967/ jnumed.115.156026. 7. Lapa P, Marques M, Costa G, et al. Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method. Nucl Med Commun. 2017;38:32532. doi:10.1097/mnm.0000000000000654. 8. Beheshti M, Mottaghy FM, Paycha F, et al. (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging. 2015;42:1767-77. doi:10.1007/ s00259-015-3138-y. 9. Li L, Li X, Jia Y, et al. Sodium-fluoride PET-CT for the non-invasive evaluation of coronary plaques in symptomatic patients with coronary artery disease: a cross-correlation study with intravascular ultrasound. Eur J Nucl Med Mol Imaging. 2018;45:2181-9. doi:10.1007/s00259-018-4122-0. 10. Papadakis G MG, Karantanas A, Marias K, et al. Application of 18F-NaF PET/CT imaging in prognosis of fractures and treatment planning in patients with fibrous dysplasia. J Nucl Med. 2017;58. 11. Papadakis G, Manikis G, Karantanas A, et al. (18) F-NaF PET/CT IMAGING IN FIBROUS DYSPLASIA OF BONE. J Bone Miner Res. 2019;34:1619-31. doi:10.1002/jbmr.3738. 12. Lee H, Lee KS, Lee WW. 18F-NaF PET/ CT Findings in Fibrous Dysplasia. Clin Nucl Med. 2015;40:912-4. doi:10.1097/ rlu.0000000000000948. 13. Schaer LR. Supraorbital fibrous dysplasia demonstrated by fluorine-18 and the scintillation (positron) camera. Radiology. 1966;86:506-8. doi:10.1148/86.3.506. 14. Keller S, Bann CM, Dodd SL, et al. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain. 2004;20:309-18. 15. Ware JE, Jr., Sherbourne CD. The MOS 36item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-83. 16. Ippolito D, Besostri V, Bonaffini PA, et al. Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM). Eur J Radiol. 2013;82:2322-7. doi:10.1016/j.ejrad.2013.08.036. 17. Lee SH, Yun SJ, Jo HH, et al. Diagnostic accuracy of low-dose versus ultra-low-dose CT for lumbar disc disease and facet joint osteoarthritis in patients with low back pain with MRI correlation. Skeletal Radiol. 2018;47:491-504. doi:10.1007/s00256-0172811-6. 6